EXACT Therapeutics first half 2026 interim report

Oslo, Norway, 3 September 2026. EXACT Therapeutics AS (the "Company", Euronext Growth ticker: EXTX), a clinical-stage precision medicine company, today announces its interim report for the first half 2026.

The interim report for the first half year 2026 is also available on the company's website: www.exact-tx.com.

For further information, please contact: Per Walday CEO EXACT Therapeutics Email: per.walday@exact-tx.com

John M. Edminson CFO EXACT Therapeutics Email: john.edminson@exact-tx.com

About EXACT Therapeutics: EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are currently traded on Euronext Growth Oslo (EXTX). An application for delisting of the shares has been approved by Oslo Stock Exchange, and last day of trading is 9 October, 2026. Further information may be found here: www.exact-tx.com